| Year |
Citation |
Score |
| 2023 |
Vaidya H, Jeong HS, Keith K, Maegawa S, Calendo G, Madzo J, Jelinek J, Issa JJ. Author Correction: DNA methylation entropy as a measure of stem cell replication and aging. Genome Biology. 24: 104. PMID 37122020 DOI: 10.1186/s13059-023-02943-8 |
0.311 |
|
| 2023 |
Vaidya H, Jeong HS, Keith K, Maegawa S, Calendo G, Madzo J, Jelinek J, Issa JJ. DNA methylation entropy as a measure of stem cell replication and aging. Genome Biology. 24: 27. PMID 36797759 DOI: 10.1186/s13059-023-02866-4 |
0.361 |
|
| 2023 |
Tricarico R, Madzo J, Scher G, Cohen M, Jelinek J, Maegawa S, Nagarathinam R, Scher C, Chang WC, Nicolas E, Slifker M, Zhou Y, Devarajan K, Cai KQ, Kwok T, ... ... Issa JP, et al. TET1 and TDG suppress inflammatory response in intestinal tumorigenesis: implications for colorectal tumors with the CpG Island Methylator Phenotype. Gastroenterology. PMID 36764492 DOI: 10.1053/j.gastro.2023.01.039 |
0.377 |
|
| 2023 |
Kim JY, Jelinek J, Lee YH, Kim DH, Kang K, Ryu SH, Moon HR, Cho K, Rha SH, Cha JK, Issa JJ, Kim J. Hypomethylation in MTNR1B: a novel epigenetic marker for atherosclerosis profiling using stenosis radiophenotype and blood inflammatory cells. Clinical Epigenetics. 15: 11. PMID 36658621 DOI: 10.1186/s13148-023-01423-x |
0.341 |
|
| 2022 |
Sun A, Park P, Cole L, Vaidya H, Maegawa S, Keith K, Calendo G, Madzo J, Jelinek J, Jobin C, Issa JJ. Non-pathogenic microbiota accelerate age-related CpG Island methylation in colonic mucosa. Epigenetics. 1-14. PMID 36572998 DOI: 10.1080/15592294.2022.2160568 |
0.375 |
|
| 2022 |
Ghosh J, Schultz BM, Chan J, Wultsch C, Singh R, Shureiqi I, Chow S, Doymaz A, Varriano S, Driscoll M, Muse J, Kleiman FE, Krampis K, Issa JJ, Sapienza C. Epigenome-Wide Study Identifies Epigenetic Outliers in Normal Mucosa of Patients with Colorectal Cancer. Cancer Prevention Research (Philadelphia, Pa.). OF1-OF12. PMID 36219239 DOI: 10.1158/1940-6207.CAPR-22-0258 |
0.354 |
|
| 2022 |
Pandey S, Djibo R, Darracq A, Calendo G, Zhang H, Henry RA, Andrews AJ, Baylin SB, Madzo J, Najmanovich R, Issa JJ, Raynal NJ. Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells. Cancers. 14. PMID 35884401 DOI: 10.3390/cancers14143340 |
0.358 |
|
| 2022 |
Issa JP. The Two-Hit Hypothesis Meets Epigenetics. Cancer Research. 82: 1167-1169. PMID 35373289 DOI: 10.1158/0008-5472.CAN-22-0405 |
0.456 |
|
| 2021 |
Panjarian S, Issa JJ. The Roles of DNA Demethylases in Triple-Negative Breast Cancer. Pharmaceuticals (Basel, Switzerland). 14. PMID 34209564 DOI: 10.3390/ph14070628 |
0.363 |
|
| 2021 |
Panjarian S, Madzo J, Keith K, Slater CM, Sapienza C, Jelinek J, Issa JJ. Accelerated aging in normal breast tissue of women with breast cancer. Breast Cancer Research : Bcr. 23: 58. PMID 34022936 DOI: 10.1186/s13058-021-01434-7 |
0.312 |
|
| 2021 |
Hu X, Estecio MR, Chen R, Reuben A, Wang L, Fujimoto J, Carrot-Zhang J, McGranahan N, Ying L, Fukuoka J, Chow CW, Pham HHN, Godoy MCB, Carter BW, Behrens C, ... ... Issa JJ, et al. Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. Nature Communications. 12: 687. PMID 33514726 DOI: 10.1038/s41467-021-20907-z |
0.3 |
|
| 2021 |
Xu J, Shi J, Cui X, Cui Y, Li JJ, Goel A, Chen X, Issa JP, Su J, Li W. Cellular Heterogeneity-Adjusted cLonal Methylation (CHALM) improves prediction of gene expression. Nature Communications. 12: 400. PMID 33452255 DOI: 10.1038/s41467-020-20492-7 |
0.45 |
|
| 2020 |
Kim JY, Choi BG, Jelinek J, Kim DH, Lee SH, Cho K, Rha SH, Lee YH, Jin HS, Choi DK, Kim GE, Kwon SU, Hwang J, Cha JK, Lee S, ... Issa JJ, et al. Promoter methylation changes in ALOX12 and AIRE1: novel epigenetic markers for atherosclerosis. Clinical Epigenetics. 12: 66. PMID 32398127 DOI: 10.1186/S13148-020-00846-0 |
0.371 |
|
| 2019 |
Majewski T, Yao H, Bondaruk J, Chung W, Lee S, Lee JG, Zhang S, Cogdell D, Yang G, Choi W, Dinney C, Grossman HB, Logothetis C, Scherer SE, Guo CC, ... ... Issa JP, et al. Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. Cell Reports. 26: 2241-2256.e4. PMID 30784602 DOI: 10.1016/j.celrep.2019.01.095 |
0.33 |
|
| 2019 |
Tao Y, Kang B, Petkovich DA, Bhandari YR, In J, Stein-O'Brien G, Kong X, Xie W, Zachos N, Maegawa S, Vaidya H, Brown S, Chiu Yen RW, Shao X, Thakor J, ... ... Issa JP, et al. Aging-like Spontaneous Epigenetic Silencing Facilitates Wnt Activation, Stemness, and Braf-Induced Tumorigenesis. Cancer Cell. 35: 315-328.e6. PMID 30753828 DOI: 10.1016/J.Ccell.2019.01.005 |
0.333 |
|
| 2019 |
Kim JY, Jelinek J, Hwang J, Shin JW, Jeong HS, Choi BG, Issa J, Kim J. Abstract WP551: Senescence-Induced Methylation Changes in Global DNA and Atherosclerosis-Related Genes in Human Vascular Endothelial Cells Stroke. 50. DOI: 10.1161/Str.50.Suppl_1.Wp551 |
0.431 |
|
| 2018 |
Zhang H, Pandey S, Travers M, Sun H, Morton G, Madzo J, Chung W, Khowsathit J, Perez-Leal O, Barrero CA, Merali C, Okamoto Y, Sato T, Pan J, Garriga J, ... ... Issa JJ, et al. Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer. Cell. 175: 1244-1258.e26. PMID 30454645 DOI: 10.1016/J.Cell.2018.09.051 |
0.335 |
|
| 2018 |
Good CR, Panjarian S, Kelly AD, Madzo J, Patel B, Jelinek J, Issa JJ. TET1-mediated hypomethylation activates oncogenic signaling in triple-negative breast cancer. Cancer Research. PMID 29891505 DOI: 10.1158/0008-5472.Can-17-2082 |
0.361 |
|
| 2018 |
Garriga J, Laumet G, Chen SR, Zhang Y, Madzo J, Issa JJ, Pan HL, Jelinek J. Nerve injury-induced chronic pain is associated with persistent DNA methylation reprogramming in dorsal root ganglion. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 29875269 DOI: 10.1523/JNEUROSCI.2616-17.2018 |
0.305 |
|
| 2018 |
Kelly AD, Madzo J, Madireddi P, Kropf P, Good CR, Jelinek J, Issa JJ. Demethylator phenotypes in acute myeloid leukemia. Leukemia. PMID 29556023 DOI: 10.1038/s41375-018-0084-2 |
0.304 |
|
| 2018 |
Jelinek J, Lee JT, Cesaroni M, Madzo J, Liang S, Lu Y, Issa JJ. Digital Restriction Enzyme Analysis of Methylation (DREAM). Methods in Molecular Biology (Clifton, N.J.). 1708: 247-265. PMID 29224148 DOI: 10.1007/978-1-4939-7481-8_13 |
0.313 |
|
| 2018 |
Kim J, Jelinek J, Hwang J, Shin JW, Jeong HS, Lee YH, Issa J, Kim J. Abstract WMP73:
Adck5, Mtnr1b
And
Kndc1
: Atherosclerosis-related Epigenetic Biomarkers Identified From Peripheral Leukocytes of Atherosclerotic Patients Stroke. 49. DOI: 10.1161/Str.49.Suppl_1.Wmp73 |
0.32 |
|
| 2018 |
Pandey S, Zhang H, Barrero CA, Merali S, Graña X, Issa J. Abstract 2995: CDK9 phosphorylates BRG1 chromatin remodeler Cancer Research. 78: 2995-2995. DOI: 10.1158/1538-7445.Am2018-2995 |
0.342 |
|
| 2017 |
Werner RJ, Kelly AD, Issa JJ. Epigenetics and Precision Oncology. Cancer Journal (Sudbury, Mass.). 23: 262-269. PMID 28926426 DOI: 10.1097/PPO.0000000000000281 |
0.417 |
|
| 2017 |
Maegawa S, Lu Y, Tahara T, Lee JT, Madzo J, Liang S, Jelinek J, Colman RJ, Issa JJ. Caloric restriction delays age-related methylation drift. Nature Communications. 8: 539. PMID 28912502 DOI: 10.1038/S41467-017-00607-3 |
0.314 |
|
| 2017 |
Good CR, Madzo J, Patel B, Maegawa S, Engel N, Jelinek J, Issa JJ. A novel isoform of TET1 that lacks a CXXC domain is overexpressed in cancer. Nucleic Acids Research. PMID 28531272 DOI: 10.1093/Nar/Gkx435 |
0.412 |
|
| 2017 |
Kelly AD, Issa JJ. The promise of epigenetic therapy: reprogramming the cancer epigenome. Current Opinion in Genetics & Development. 42: 68-77. PMID 28412585 DOI: 10.1016/j.gde.2017.03.015 |
0.425 |
|
| 2017 |
Sato T, Issa JJ, Kropf P. DNA Hypomethylating Drugs in Cancer Therapy. Cold Spring Harbor Perspectives in Medicine. PMID 28159832 DOI: 10.1101/cshperspect.a026948 |
0.434 |
|
| 2017 |
Issa J. Abstract IA15: Multiple targetable pathways for epigenetic therapy Cancer Research. 77. DOI: 10.1158/1538-7445.Newfront17-Ia15 |
0.474 |
|
| 2017 |
Deliard S, Okamoto Y, Madzo J, Jelinek J, Issa J. Abstract LB-100: Potential role of the splicing factor SF3B1 in epigenetic regulation Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-100 |
0.507 |
|
| 2017 |
Good CR, Kelly A, Madzo J, Jelinek J, Issa J. Abstract 3359: TET1 mediated hypomethylation activates oncogenic signaling pathways in triple negative breast cancer Cancer Research. 77: 3359-3359. DOI: 10.1158/1538-7445.Am2017-3359 |
0.467 |
|
| 2016 |
Raynal NJ, Da Costa EM, Lee JT, Gharibyan V, Ahmed S, Zhang H, Sato T, Malouf GG, Issa JJ. REPOSITIONING FDA-APPROVED DRUGS IN COMBINATION WITH EPIGENETIC DRUGS TO REPROGRAM COLON CANCER EPIGENOME. Molecular Cancer Therapeutics. PMID 27980103 DOI: 10.1158/1535-7163.MCT-16-0588 |
0.334 |
|
| 2016 |
Sato T, Cesaroni M, Chung W, Panjarian S, Tran A, Madzo J, Okamoto Y, Zhang H, Chen X, Jelinek J, Issa JJ. Transcriptional Selectivity of Epigenetic Therapy in Cancer. Cancer Research. PMID 27879268 DOI: 10.1158/0008-5472.Can-16-0834 |
0.45 |
|
| 2016 |
Jones PA, Issa JJ, Baylin S. Targeting the cancer epigenome for therapy. Nature Reviews. Genetics. 17: 630-641. PMID 27629931 DOI: 10.1038/Nrg.2016.93 |
0.316 |
|
| 2016 |
Overman MJ, Morris V, Moinova H, Manyam G, Ensor J, Lee MS, Eng C, Kee B, Fogelman D, Shroff RT, LaFramboise T, Mazard T, Feng T, Hamilton S, Broom B, ... ... Issa JP, et al. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget. PMID 27542211 DOI: 10.18632/Oncotarget.11317 |
0.324 |
|
| 2016 |
Sapienza C, Issa JP. Diet, Nutrition, and Cancer Epigenetics. Annual Review of Nutrition. PMID 27022771 DOI: 10.1146/Annurev-Nutr-121415-112634 |
0.351 |
|
| 2016 |
Kleb B, Estécio MR, Zhang J, Tzelepi V, Chung W, Jelinek J, Navone NM, Tahir S, Marquez VE, Issa JP, Maity S, Aparicio A. Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas. Epigenetics. 0. PMID 26890396 DOI: 10.1080/15592294.2016.1146851 |
0.358 |
|
| 2016 |
Yamazaki J, Taby R, Jelinek J, Raynal NJ, Cesaroni M, Pierce SA, Kornblau SM, Bueso-Ramos CE, Ravandi F, Kantarjian HM, Issa JP. Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia. Journal of the National Cancer Institute. 108. PMID 26568194 DOI: 10.1093/jnci/djv323 |
0.375 |
|
| 2016 |
Sato T, Cesaroni M, Tran A, Madzo J, Okamoto Y, Zhang H, Panjarian S, Jelinek J, Issa J. Abstract B42: Decitabine specifically targets genes that gain DNA methylation and lose expression in cancer and can be combined with histone methylation inhibitors for increased efficacy Cancer Research. 76. DOI: 10.1158/1538-7445.Chromepi15-B42 |
0.556 |
|
| 2016 |
madireddi p, Jelinek J, Lee J, Sato T, Issa J. Abstract 4442: Very low methylation is a novel epigenetic regulatory mechanism in normal tissues and predisposes to hypermethylation in cancer Cancer Research. 76: 4442-4442. DOI: 10.1158/1538-7445.Am2016-4442 |
0.565 |
|
| 2016 |
Sun A, Jelinek J, Maegawa S, Jobin C, Issa J. Abstract 4441: Non-pathogenic bacteria change host DNA methylationin vivo Cancer Research. 76: 4441-4441. DOI: 10.1158/1538-7445.Am2016-4441 |
0.445 |
|
| 2016 |
Kang B, In J, Zachos N, Huso D, Maegawa S, Issa J, Easwaran H, Baylin SB. Abstract 4273: Oncogenic BRAFV600E drives stem cell niche factors-independent growth and tumorigenic transformation in colon organoids Cancer Research. 76: 4273-4273. DOI: 10.1158/1538-7445.Am2016-4273 |
0.413 |
|
| 2016 |
Good CR, Madzo J, Maegawa S, Engel N, Jelinek J, Issa J. Abstract 2659: A novel isoform of TET1 that lacks a CXXC domain is overexpressed in cancer Cancer Research. 76: 2659-2659. DOI: 10.1158/1538-7445.Am2016-2659 |
0.526 |
|
| 2015 |
Raynal NJ, Lee JT, Wang Y, Beaudry A, Madireddi P, Garriga J, Malouf GG, Dumont S, Dettman EJ, Gharibyan V, Ahmed S, Chung W, Childers WE, Abou-Gharbia M, Henry RA, ... ... Issa JJ, et al. Targeting calcium signaling induces epigenetic reactivation of tumor suppressor genes in cancer. Cancer Research. PMID 26719529 DOI: 10.1158/0008-5472.Can-14-2391 |
0.384 |
|
| 2015 |
Bouwmeester MC, Ruiter S, Lommelaars T, Sippel J, Hodemaekers HM, van den Brandhof EJ, Pennings JL, Kamstra JH, Jelinek J, Issa JJ, Legler J, van der Ven LT. Zebrafish embryos as a screen for DNA methylation modifications after compound exposure. Toxicology and Applied Pharmacology. 291: 84-96. PMID 26712470 DOI: 10.1016/j.taap.2015.12.012 |
0.343 |
|
| 2015 |
Jin C, Qin T, Barton MC, Jelinek J, Issa JJ. Minimal Role of Base Excision Repair in TET-Induced Global DNA Demethylation in HEK293T Cells. Epigenetics. 0. PMID 26440216 DOI: 10.1080/15592294.2015.1091145 |
0.768 |
|
| 2015 |
Qin T, Si J, Raynal NJ, Wang X, Gharibyan V, Ahmed S, Hu X, Jin C, Lu Y, Shu J, Estecio MR, Jelinek J, Issa JP. Epigenetic synergy between decitabine and platinum derivatives. Clinical Epigenetics. 7: 97. PMID 26366234 DOI: 10.1186/S13148-015-0131-Z |
0.793 |
|
| 2015 |
Foy JP, Pickering CR, Papadimitrakopoulou VA, Jelinek J, Lin SH, William WN, Mitchell FT, Wang J, Lang W, Feng L, Zhang L, Kim ES, Fan YH, Hong WK, El-Naggar A, ... ... Issa JJ, et al. New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development. Cancer Prevention Research (Philadelphia, Pa.). PMID 26342026 DOI: 10.1158/1940-6207.Capr-14-0179 |
0.487 |
|
| 2015 |
Malouf GG, Tahara T, Paradis V, Fabre M, Guettier C, Yamazaki J, Long H, Lu Y, Raynal NJ, Jelinek J, Mouawad R, Khayat D, Brugières L, Raymond E, Issa JP. Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features. Epigenetics. 10: 872-81. PMID 26224146 DOI: 10.1080/15592294.2015.1076955 |
0.427 |
|
| 2015 |
Fujii S, Srivastava V, Hegde A, Kondo Y, Shen L, Hoshino K, Gonzalez Y, Wang J, Sasai K, Ma X, Katayama H, Estecio MR, Hamilton SR, Wistuba I, Issa JP, et al. Regulation of AURKC expression by CpG island methylation in human cancer cells. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. PMID 25990457 DOI: 10.1007/s13277-015-3553-5 |
0.432 |
|
| 2015 |
Yamazaki J, Jelinek J, Lu Y, Cesaroni M, Madzo J, Neumann F, He R, Taby R, Vasanthakumar A, Macrae T, Ostler KR, Kantarjian HM, Liang S, Estecio MR, Godley LA, ... Issa JP, et al. TET2 mutations affect non-CpG island DNA methylation at enhancers and transcription factor binding sites in chronic myelomonocytic leukemia. Cancer Research. PMID 25972343 DOI: 10.1158/0008-5472.Can-14-0739 |
0.389 |
|
| 2015 |
Tsimberidou AM, Said R, Culotta K, Wistuba I, Jelinek J, Fu S, Falchook G, Naing A, Piha-Paul S, Zinner R, Siddik ZH, He G, Hess K, Stewart DJ, Kurzrock R, ... Issa JP, et al. Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clinical Epigenetics. 7: 29. PMID 25806091 DOI: 10.1186/S13148-015-0065-5 |
0.339 |
|
| 2015 |
Kropf PL, Pancari PA, Fung H, Kantarjian HM, Xiao L, Xuelin H, Issa J. Superior Response Rates for Patients with Myeloid Malignancies Treated with the Combination of Decitabine (DAC) and Arsenic Trioxide (ATO) in a Phase II Adaptive Three Arm Randomization Study: DAC +/- Carboplatin or ATO Blood. 126: 3775-3775. DOI: 10.1182/Blood.V126.23.3775.3775 |
0.32 |
|
| 2015 |
Gottipati S, Rohatagi S, Chung W, Taverna P, Kantarjian HM, Roboz GJ, Kropf PL, Azab M, Issa J. Multivariate Analysis Identifies Significant Correlations Between Baseline Biomarkers, DNA Demethylation and Clinical Responses in 122 Patients Treated in a Phase 1/2, Study of Guadecitabine (SGI-110), in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (r/r AML) Blood. 126: 2594-2594. DOI: 10.1182/Blood.V126.23.2594.2594 |
0.401 |
|
| 2015 |
Sato T, Cesaroni M, Jelinek J, Issa J. Abstract 3521: Combined targeting of DNA and histone methylation improves the efficacy and specificity of epigenetic therapy Cancer Research. 75: 3521-3521. DOI: 10.1158/1538-7445.Am2015-3521 |
0.531 |
|
| 2015 |
Madireddi P, Jelinek J, Lee J, Cesaroni M, Rodrigues R, Zhang Y, Issa J. Abstract 2954: Low level methylation (1-20%) or methylation seeds is a distinct epigenetic regulator of gene expression and is a strong predictor of methylation gains in AML and MDS patients Cancer Research. 75: 2954-2954. DOI: 10.1158/1538-7445.Am2015-2954 |
0.546 |
|
| 2015 |
Sun A, Cesaroni M, Jobin C, Barrero C, Jelinek J, Sautter JD, Rams TE, Merali S, Issa J. Abstract 2889: Distinct microbiome in colorectal cancers with the CpG Island Methylator Phenotype Cancer Research. 75: 2889-2889. DOI: 10.1158/1538-7445.Am2015-2889 |
0.383 |
|
| 2015 |
Panjarian SB, Slater C, Madzo J, Jelinek J, Chen X, Issa J. Abstract 1071: Age-dependent DNA methylation in normal breast epithelium and breast cancer Cancer Research. 75: 1071-1071. DOI: 10.1158/1538-7445.Am2015-1071 |
0.512 |
|
| 2014 |
Cui Y, Hausheer F, Beaty R, Zahnow C, Issa JP, Bunz F, Baylin SB. A recombinant reporter system for monitoring reactivation of an endogenously DNA hypermethylated gene. Cancer Research. 74: 3834-43. PMID 24876104 DOI: 10.1158/0008-5472.Can-13-2287 |
0.484 |
|
| 2014 |
Jin C, Lu Y, Jelinek J, Liang S, Estecio MR, Barton MC, Issa JP. TET1 is a maintenance DNA demethylase that prevents methylation spreading in differentiated cells. Nucleic Acids Research. 42: 6956-71. PMID 24875481 DOI: 10.1093/Nar/Gku372 |
0.453 |
|
| 2014 |
Pathiraja TN, Nayak SR, Xi Y, Jiang S, Garee JP, Edwards DP, Lee AV, Chen J, Shea MJ, Santen RJ, Gannon F, Kangaspeska S, Jelinek J, Issa JP, Richer JK, et al. Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Science Translational Medicine. 6: 229ra41. PMID 24670685 DOI: 10.1126/Scitranslmed.3008326 |
0.418 |
|
| 2014 |
Maegawa S, Gough SM, Watanabe-Okochi N, Lu Y, Zhang N, Castoro RJ, Estecio MR, Jelinek J, Liang S, Kitamura T, Aplan PD, Issa JP. Age-related epigenetic drift in the pathogenesis of MDS and AML. Genome Research. 24: 580-91. PMID 24414704 DOI: 10.1101/Gr.157529.113 |
0.418 |
|
| 2014 |
Tahara T, Yamamoto E, Madireddi P, Suzuki H, Maruyama R, Chung W, Garriga J, Jelinek J, Yamano HO, Sugai T, Kondo Y, Toyota M, Issa JP, Estécio MR. Colorectal carcinomas with CpG island methylator phenotype 1 frequently contain mutations in chromatin regulators. Gastroenterology. 146: 530-38.e5. PMID 24211491 DOI: 10.1053/j.gastro.2013.10.060 |
0.338 |
|
| 2014 |
Okamoto Y, Shinjo K, Shimizu Y, Sano T, Yamao K, Gao W, Fujii M, Osada H, Sekido Y, Murakami S, Tanaka Y, Joh T, Sato S, Takahashi S, Wakita T, ... ... Issa JP, et al. Hepatitis virus infection affects DNA methylation in mice with humanized livers. Gastroenterology. 146: 562-72. PMID 24184133 DOI: 10.1053/j.gastro.2013.10.056 |
0.334 |
|
| 2014 |
Garcia-Manero G, Ritchie EK, Walsh K, Savona M, Kropf P, O'Connell C, Tibes R, Daver NG, Jabbour E, Lunin S, Rosenblat TL, Yee K, Stock W, Griffiths EA, Mace JR, ... ... Issa J, et al. First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Blood. 124: 529-529. DOI: 10.1182/Blood.V124.21.529.529 |
0.318 |
|
| 2014 |
Kim SJ, Swierczek S, Song J, Issa J, Jelinek J, Prchal JT. Focal Reactivation of X-Chromosome in Female Patients with PV and ET Blood. 124: 3225-3225. DOI: 10.1182/Blood.V124.21.3225.3225 |
0.364 |
|
| 2014 |
Tsimberidou AM, Culotta K, Wistuba I, Fu S, Naing A, Falchook G, Piha-Paul S, Zinner R, Rodriguez-Canales J, He G, Siddik ZH, Jelinek J, Chung W, Ye Y, Said R, ... ... Issa J, et al. Abstract CT201: Phase I study of 5-azacytidine and oxaliplatin in patients with advanced cancers relapsed or refractory to platinum compounds Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct201 |
0.373 |
|
| 2014 |
Czerniak BA, Lee S, Bondaruk J, Lee S, Majewski T, Zhang S, Shen L, Liu Y, Guo C, Dinney C, Grossman HB, Zhang W, Bar-Eli M, Baggerly K, Behringer R, ... ... Issa J, et al. Abstract 5256: Mechanism of field cancerization Cancer Research. 74: 5256-5256. DOI: 10.1158/1538-7445.Am2014-5256 |
0.396 |
|
| 2014 |
Zhang H, Raynal NJ, Jacobson MA, Issa J. Abstract 378: Discovering potential epigenetic anti-cancer drugs derived from natural compounds Cancer Research. 74: 378-378. DOI: 10.1158/1538-7445.Am2014-378 |
0.53 |
|
| 2014 |
Okamoto Y, Yamazaki J, Sato T, Cesaroni M, Chung W, Garriga J, Jelinek J, Katz RA, Issa J. Abstract 373: An siRNA screen identifies CHD4 as a target for epigenetic therapy Cancer Research. 74: 373-373. DOI: 10.1158/1538-7445.Am2014-373 |
0.543 |
|
| 2014 |
Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Aldaz CM, Issa J, Kurzrock R, Wistuba II. Abstract 2303: Decitabine impact on immunohistochemistry scores for tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in human tumor samples Cancer Research. 74: 2303-2303. DOI: 10.1158/1538-7445.Am2014-2303 |
0.405 |
|
| 2013 |
Malouf GG, Taube JH, Lu Y, Roysarkar T, Panjarian S, Estecio MR, Jelinek J, Yamazaki J, Raynal NJ, Long H, Tahara T, Tinnirello A, Ramachandran P, Zhang XY, Liang S, ... ... Issa JP, et al. Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition. Genome Biology. 14: R144. PMID 24367927 DOI: 10.1186/Gb-2013-14-12-R144 |
0.37 |
|
| 2013 |
Tahara T, Maegawa S, Chung W, Garriga J, Jelinek J, Estécio MR, Shibata T, Hirata I, Arisawa T, Issa JP. Examination of whole blood DNA methylation as a potential risk marker for gastric cancer. Cancer Prevention Research (Philadelphia, Pa.). 6: 1093-100. PMID 23943784 DOI: 10.1158/1940-6207.CAPR-13-0034 |
0.373 |
|
| 2013 |
Yamazaki J, Estecio MR, Lu Y, Long H, Malouf GG, Graber D, Huo Y, Ramagli L, Liang S, Kornblau SM, Jelinek J, Issa JP. The epigenome of AML stem and progenitor cells. Epigenetics. 8: 92-104. PMID 23249680 DOI: 10.4161/Epi.23243 |
0.368 |
|
| 2013 |
Kantarjian HM, Jabbour E, Yee K, Kropf P, O'Connell C, Stock W, Tibes R, Rizzieri D, Walsh K, Griffiths EA, Roboz GJ, Savona M, Ervin T, Podoltsev NA, Pemmaraju N, ... ... Issa J, et al. First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML) Blood. 122: 497-497. DOI: 10.1182/Blood.V122.21.497.497 |
0.31 |
|
| 2013 |
Chung W, Taverna P, Lyons JF, Hao Y, Azab M, Kantarjian HM, Kropf P, Issa J. Determinants Of Demethylation and Clinical Response In AML Patients Treated With SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA) In a Phase 1 Study Blood. 122: 1442-1442. DOI: 10.1182/Blood.V122.21.1442.1442 |
0.417 |
|
| 2013 |
Issa J. Abstract ED02-01: Epigenetic variation as the missing link between aging and cancer Cancer Prevention Research. 6. DOI: 10.1158/1940-6215.Prev-13-Ed02-01 |
0.509 |
|
| 2013 |
Malouf GG, Su X, Yao H, Wood CG, Lu Y, Liang S, Thompson EJ, Doss DJ, Jelinek J, Issa J, Tannir NM. Abstract 2980: Integrated transcriptome and methylome sequencing of Xp11 translocation renal cell carcinomas reveal uncoupling of DNA methylation and transcriptional profiles. Cancer Research. 73: 2980-2980. DOI: 10.1158/1538-7445.Am2013-2980 |
0.525 |
|
| 2012 |
Overman MJ, Eng C, Kee BK, Fogelman DR, Fark C, Hippert R, Holter S, Issa JP, Hamilton SR, Kopetz S. A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory metastatic colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 450. PMID 27983228 DOI: 10.1200/Jco.2012.30.4_Suppl.450 |
0.399 |
|
| 2012 |
Jelinek J, Liang S, Lu Y, He R, Ramagli LS, Shpall EJ, Estecio MR, Issa JP. Conserved DNA methylation patterns in healthy blood cells and extensive changes in leukemia measured by a new quantitative technique. Epigenetics. 7: 1368-78. PMID 23075513 DOI: 10.4161/Epi.22552 |
0.444 |
|
| 2012 |
Estécio MR, Gallegos J, Dekmezian M, Lu Y, Liang S, Issa JP. SINE retrotransposons cause epigenetic reprogramming of adjacent gene promoters. Molecular Cancer Research : McR. 10: 1332-42. PMID 22952045 DOI: 10.1158/1541-7786.MCR-12-0351 |
0.477 |
|
| 2012 |
Ulrich CM, Toriola AT, Koepl LM, Sandifer T, Poole EM, Duggan C, McTiernan A, Issa JP. Metabolic, hormonal and immunological associations with global DNA methylation among postmenopausal women. Epigenetics. 7: 1020-8. PMID 22869041 DOI: 10.4161/Epi.21464 |
0.366 |
|
| 2012 |
Xu J, Shetty PB, Feng W, Chenault C, Bast RC, Issa JP, Hilsenbeck SG, Yu Y. Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. Bmc Cancer. 12: 243. PMID 22695491 DOI: 10.1186/1471-2407-12-243 |
0.317 |
|
| 2012 |
Boumber Y, Kantarjian H, Jorgensen J, Wen S, Faderl S, Castoro R, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes J, Issa JP, Ravandi F. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia. 26: 2428-31. PMID 22665218 DOI: 10.1038/Leu.2012.153 |
0.613 |
|
| 2012 |
Zhang Y, Shu J, Si J, Shen L, Estecio MR, Issa JP. Repetitive elements and enforced transcriptional repression co-operate to enhance DNA methylation spreading into a promoter CpG-island. Nucleic Acids Research. 40: 7257-68. PMID 22600741 DOI: 10.1093/Nar/Gks429 |
0.812 |
|
| 2012 |
Issa JP. DNA methylation as a clinical marker in oncology. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2566-8. PMID 22564986 DOI: 10.1200/Jco.2012.42.1016 |
0.573 |
|
| 2012 |
Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, Harris J, Yen RW, Ahuja N, Brock MV, Stearns V, ... ... Issa JP, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 21: 430-46. PMID 22439938 DOI: 10.1016/J.Ccr.2011.12.029 |
0.409 |
|
| 2012 |
Yamazaki J, Taby R, Vasanthakumar A, Macrae T, Ostler KR, Shen L, Kantarjian HM, Estecio MR, Jelinek J, Godley LA, Issa JP. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics. 7: 201-7. PMID 22395470 DOI: 10.4161/Epi.7.2.19015 |
0.379 |
|
| 2012 |
Bhardwaj A, Song HW, Beildeck M, Kerkhofs S, Castoro R, Shanker S, De Gendt K, Suzuki K, Claessens F, Issa JP, Orgebin-Crist MC, Wilkinson MF. DNA demethylation-dependent AR recruitment and GATA factors drive Rhox5 homeobox gene transcription in the epididymis. Molecular Endocrinology (Baltimore, Md.). 26: 538-49. PMID 22322598 DOI: 10.1210/Me.2011-1059 |
0.328 |
|
| 2012 |
Raynal NJ, Si J, Taby RF, Gharibyan V, Ahmed S, Jelinek J, Estécio MR, Issa JP. DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Research. 72: 1170-81. PMID 22219169 DOI: 10.1158/0008-5472.Can-11-3248 |
0.833 |
|
| 2012 |
Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS, Bock C, Vasanthakumar A, Gu H, Xi Y, Liang S, Lu Y, Darlington GJ, Meissner A, Issa JP, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nature Genetics. 44: 23-31. PMID 22138693 DOI: 10.1038/Ng.1009 |
0.365 |
|
| 2012 |
Saintigny P, Lang W, Jelinek J, Pickering CR, Feng L, Frederick MJ, Zhang L, Ren H, Lee JJ, Kim ES, Fan YH, El-Naggar AK, Hong WK, Myers J, Papadimitrakopoulou V, ... Issa J, et al. New DNA methylation markers associated with oral cancer (OC) development (dvlpt). Journal of Clinical Oncology. 30: 5524-5524. DOI: 10.1200/Jco.2012.30.15_Suppl.5524 |
0.516 |
|
| 2012 |
Gough SM, Chung YJ, Shinji M, Jelinek J, Issa J, Aplan P. Mice with Myelodysplastic Syndrome Respond to Treatment with Azanucleosides: A Preclinical Model for MDS Therapies Blood. 120: 3829-3829. DOI: 10.1182/Blood.V120.21.3829.3829 |
0.406 |
|
| 2012 |
Tsai H, Li H, Neste LV, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, Harris J, Yen RC, Ahuja N, Brock MV, Stearns V, ... ... Issa J, et al. Abstract 995: Transient low doses of DNA demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells Cancer Research. 72: 995-995. DOI: 10.1158/1538-7445.Am2012-995 |
0.509 |
|
| 2012 |
Kleb BN, Estecio M, Zhang J, Tzelepi V, Chung W, Maity S, Logothetis C, Troncoso P, Navone N, Jelinek J, Liang S, Issa J, Aparicio A. Abstract 991: The DNA methylome of castration-resistant prostate cancer Cancer Research. 72: 991-991. DOI: 10.1158/1538-7445.Am2012-991 |
0.441 |
|
| 2012 |
Plimack ER, Issa J, Jelinek J, Sharma P, Vence L, Bassett RL, Ilagan JL, Papadopoulos NE, Hwu W. Abstract 5590: A phase I/II study of decitabine with pegylated interferon α-2b in advanced melanoma: clinical results and impact on DNA methylation and immune modulation Cancer Research. 72: 5590-5590. DOI: 10.1158/1538-7445.Am2012-5590 |
0.371 |
|
| 2012 |
Czerniak BA, Majewski T, Bondaruk J, Zhang S, Lee S, Baggerly K, Dinney C, Grossman HB, Wu X, Issa J, Zhang W, Gibbs R, Scherer SE. Abstract 5066: Genome sequence and epigenome map of bladder cancer development from occult field effects Cancer Research. 72: 5066-5066. DOI: 10.1158/1538-7445.Am2012-5066 |
0.373 |
|
| 2012 |
Guillaumet A, Sandoval J, Esteller M, Issa J, Sibert R, Monk D. Abstract 4021: Breaking the dogma: AWT1 hypermethylation in myeloid leukemia despite high expression Cancer Research. 72: 4021-4021. DOI: 10.1158/1538-7445.Am2012-4021 |
0.551 |
|
| 2011 |
Konishi K, Watanabe Y, Shen L, Guo Y, Castoro RJ, Kondo K, Chung W, Ahmed S, Jelinek J, Boumber YA, Estecio MR, Maegawa S, Kondo Y, Itoh F, Imawari M, ... ... Issa JP, et al. DNA methylation profiles of primary colorectal carcinoma and matched liver metastasis. Plos One. 6: e27889. PMID 22132162 DOI: 10.1371/Journal.Pone.0027889 |
0.699 |
|
| 2011 |
Qin T, Castoro R, El Ahdab S, Jelinek J, Wang X, Si J, Shu J, He R, Zhang N, Chung W, Kantarjian HM, Issa JP. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. Plos One. 6: e23372. PMID 21858090 DOI: 10.1371/Journal.Pone.0023372 |
0.744 |
|
| 2011 |
Issa JP. Epigenetic variation and cellular Darwinism Nature Genetics. 43: 724-726. PMID 21792236 DOI: 10.1038/Ng.897 |
0.483 |
|
| 2011 |
Jelinek J, Gharibyan V, Estecio MR, Kondo K, He R, Chung W, Lu Y, Zhang N, Liang S, Kantarjian HM, Cortes JE, Issa JP. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. Plos One. 6: e22110. PMID 21760961 DOI: 10.1371/Journal.Pone.0022110 |
0.484 |
|
| 2011 |
Issa JP, Just W. Epigenetics. Febs Letters. 585: 1993. PMID 21693122 DOI: 10.1016/j.febslet.2011.06.007 |
0.326 |
|
| 2011 |
Chung W, Bondaruk J, Jelinek J, Lotan Y, Liang S, Czerniak B, Issa JP. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 20: 1483-91. PMID 21586619 DOI: 10.1158/1055-9965.Epi-11-0067 |
0.36 |
|
| 2011 |
Boumber Y, Issa JPJ. Epigenetics in cancer: what's the future? Oncology (Williston Park, N.Y.). 25. PMID 21548464 DOI: 10.1016/j.febslet.2011.06.007 |
0.738 |
|
| 2011 |
Ahn JB, Chung WB, Maeda O, Shin SJ, Kim HS, Chung HC, Kim NK, Issa JP. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer. 117: 1847-54. PMID 21509761 DOI: 10.1002/cncr.25737 |
0.336 |
|
| 2011 |
Pathiraja TN, Shetty PB, Jelinek J, He R, Hartmaier R, Margossian AL, Hilsenbeck SG, Issa JP, Oesterreich S. Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4177-86. PMID 21459801 DOI: 10.1158/1078-0432.CCR-10-2950 |
0.344 |
|
| 2011 |
Cogdell D, Chung W, Liu Y, McDonald JM, Aldape K, Issa JP, Fuller GN, Zhang W. Tumor-associated methylation of the putative tumor suppressor AJAP1 gene and association between decreased AJAP1 expression and shorter survival in patients with glioma. Chinese Journal of Cancer. 30: 247-53. PMID 21439246 DOI: 10.5732/Cjc.011.10025 |
0.409 |
|
| 2011 |
Estécio MRH, Issa JPJ. Dissecting DNA hypermethylation in cancer Febs Letters. 585: 2078-2086. PMID 21146531 DOI: 10.1016/j.febslet.2010.12.001 |
0.473 |
|
| 2011 |
Jelinek J, Liang S, Neumann F, He R, Lu Y, Yamazaki J, Taby RF, Ramagli L, Estecio MR, Issa J. Cancer Drivers Affected by Aberrant DNA Methylation in MDS and AML Blood. 118: 1716-1716. DOI: 10.1182/Blood.V118.21.1716.1716 |
0.54 |
|
| 2011 |
Boumber Y, Issa J, Jorgensen JL, Faderl S, Castoro RJ, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes JE, Kantarjian HM, Ravandi F. Final Report of a Randomized Study of Decitabine Versus Conventional Care (CC) for Maintenance Therapy in Patients with Intermediate and High Risk Acute Myeloid Leukemia (AML) in First or Subsequent Complete Remission (CR) Blood. 118: 1530-1530. DOI: 10.1182/Blood.V118.21.1530.1530 |
0.657 |
|
| 2011 |
Yamazaki J, Taby RF, Vasanthakumar A, Macrae T, Ostler KR, Shen L, Kantarjian HM, Estecio MR, Jelinek J, Godley L, Issa J. Limited Effect of TET2 Mutations on Promoter DNA Methylation in Chronic Myelomonocytic Leukemia Blood. 118: 1365-1365. DOI: 10.1182/Blood.V118.21.1365.1365 |
0.503 |
|
| 2011 |
Czerniak B, Majewski T, Chung W, Limei H, Cogdell D, Bondaruk J, Zhang S, Lee S, Lee S, Shen L, Wei C, Yoo SY, Choi W, McConkey D, Weinstein J, ... ... Issa J, et al. Abstract 4837: Integrated genome sequence, epigenome, and transcriptome map of bladder cancer development Cancer Research. 71: 4837-4837. DOI: 10.1158/1538-7445.Am2011-4837 |
0.384 |
|
| 2011 |
Estecio MRH, Dekmezian M, Gallegos J, Liang S, Issa J. Abstract 2791: SINE retrotransposons cause epigenetic reprogramming of adjacent gene promoters Cancer Research. 71: 2791-2791. DOI: 10.1158/1538-7445.Am2011-2791 |
0.492 |
|
| 2010 |
Wallace K, Grau MV, Levine AJ, Shen L, Hamdan R, Chen X, Gui J, Haile RW, Barry EL, Ahnen D, McKeown-Eyssen G, Baron JA, Issa JP. Association between folate levels and CpG Island hypermethylation in normal colorectal mucosa. Cancer Prevention Research (Philadelphia, Pa.). 3: 1552-64. PMID 21149331 DOI: 10.1158/1940-6207.Capr-10-0047 |
0.365 |
|
| 2010 |
Taby R, Issa JP. Cancer epigenetics Ca Cancer Journal For Clinicians. 60: 376-392. PMID 20959400 DOI: 10.3322/caac.20085 |
0.371 |
|
| 2010 |
Estécio MR, Gallegos J, Vallot C, Castoro RJ, Chung W, Maegawa S, Oki Y, Kondo Y, Jelinek J, Shen L, Hartung H, Aplan PD, Czerniak BA, Liang S, Issa JP. Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer. Genome Research. 20: 1369-82. PMID 20716667 DOI: 10.1101/Gr.107318.110 |
0.476 |
|
| 2010 |
Si J, Boumber YA, Shu J, Qin T, Ahmed S, He R, Jelinek J, Issa JP. Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation. Cancer Research. 70: 6968-77. PMID 20713525 DOI: 10.1158/0008-5472.Can-09-4474 |
0.77 |
|
| 2010 |
Kondo Y, Issa JPJ. DNA methylation profiling in cancer Expert Reviews in Molecular Medicine. 12. PMID 20663272 DOI: 10.1017/S1462399410001559 |
0.443 |
|
| 2010 |
Kwabi-Addo B, Wang S, Chung W, Jelinek J, Patierno SR, Wang BD, Andrawis R, Lee NH, Apprey V, Issa JP, Ittmann M. Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3539-47. PMID 20606036 DOI: 10.1158/1078-0432.Ccr-09-3342 |
0.376 |
|
| 2010 |
Issa JP. Epigenetic changes in the myelodysplastic syndrome Hematology/Oncology Clinics of North America. 24: 317-330. PMID 20359628 DOI: 10.1016/J.Hoc.2010.02.007 |
0.539 |
|
| 2010 |
Oki Y, Issa JPJ. Epigenetic mechanisms in AML - A target for therapy Cancer Treatment and Research. 145: 19-40. PMID 20306243 DOI: 10.1007/978-0-387-69259-3_2 |
0.431 |
|
| 2010 |
An B, Kondo Y, Okamoto Y, Shinjo K, Kanemitsu Y, Komori K, Hirai T, Sawaki A, Tajika M, Nakamura T, Yamao K, Yatabe Y, Fujii M, Murakami H, Osada H, ... ... Issa JP, et al. Characteristic methylation profile in CpG island methylator phenotype-negative distal colorectal cancers. International Journal of Cancer. Journal International Du Cancer. 127: 2095-105. PMID 20131317 DOI: 10.1002/ijc.25225 |
0.44 |
|
| 2010 |
Maegawa S, Hinkal G, Kim HS, Shen L, Zhang L, Zhang J, Zhang N, Liang S, Donehower LA, Issa JP. Widespread and tissue specific age-related DNA methylation changes in mice. Genome Research. 20: 332-40. PMID 20107151 DOI: 10.1101/Gr.096826.109 |
0.366 |
|
| 2010 |
Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, ... Issa JP, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 605-13. PMID 20038729 DOI: 10.1200/JCO.2009.23.4781 |
0.308 |
|
| 2010 |
Santos FP, Kantarjian H, Garcia-Manero G, Issa JP, Ravandi F. Decitabine in the treatment of myelodysplastic syndromes. Expert Review of Anticancer Therapy. 10: 9-22. PMID 20014881 DOI: 10.1586/era.09.164 |
0.343 |
|
| 2010 |
Suzuki H, Igarashi S, Nojima M, Maruyama R, Yamamoto E, Kai M, Akashi H, Watanabe Y, Yamamoto H, Sasaki Y, Itoh F, Imai K, Sugai T, Shen L, Issa JPJ, et al. IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype Carcinogenesis. 31: 342-349. PMID 19638426 DOI: 10.1093/carcin/bgp179 |
0.43 |
|
| 2010 |
Kashani FR, Jorgensen J, Faderl S, Issa J, Autry J, Garcia-Manero G, Borthakur G, Huang X, Cortes JE, Kantarjian H. Randomized study of decitabine versus conventional care (CC) in patients (pts) with intermediate- and high-risk acute myeloid leukemia (AML) in first or subsequent complete remission (CR). Journal of Clinical Oncology. 28: 6527-6527. DOI: 10.1200/Jco.2010.28.15_Suppl.6527 |
0.336 |
|
| 2010 |
Yamazaki J, Estecio MR, Jelinek J, Graber D, Lu Y, Ramagli L, Liang S, Kornblau SM, Issa J. Genome-Wide Epigenetic Analysis of Cancer Stem Cells (CSCs) In Acute Myeloid Leukemia. Blood. 116: 3640-3640. DOI: 10.1182/Blood.V116.21.3640.3640 |
0.479 |
|
| 2010 |
Neumann F, Issa J, Lu Y, Estecio MR, He R, Ramagli L, Liang S, Jelinek J. Digital Restriction Enzyme Analysis of Methylation (DREAM) by Next Generation Sequencing Uncovers Epigenetic Disturbances In Acute Myelogenous Leukemia. Blood. 116: 3635-3635. DOI: 10.1182/Blood.V116.21.3635.3635 |
0.527 |
|
| 2010 |
Yan Z, Shu J, Si J, Qin T, Estecio MR, Issa J. Abstract LB-84: DNA methylation centers in CpG-island promoters are context-specific Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-84 |
0.812 |
|
| 2009 |
Stewart DJ, Nunez MI, Jelinek J, Guo Z, Hong D, Gupta S, Oki Y, Issa J, Kurzrock R, Wistuba II. Decitabine effect on human tumor expression of various transporters. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2540. PMID 27961867 DOI: 10.1200/Jco.2009.27.15_Suppl.2540 |
0.383 |
|
| 2009 |
Liang S, Lu Y, Jelinek J, Estecio M, Li H, Issa JP. Analysis of epigenetic modifications by next generation sequencing. Conference Proceedings : ... Annual International Conference of the Ieee Engineering in Medicine and Biology Society. Ieee Engineering in Medicine and Biology Society. Annual Conference. 2009: 6730. PMID 19963934 DOI: 10.1109/IEMBS.2009.5332853 |
0.395 |
|
| 2009 |
Estécio MR, Issa JP. Tackling the methylome: recent methodological advances in genome-wide methylation profiling. Genome Medicine. 1: 106. PMID 19930617 DOI: 10.1186/gm106 |
0.452 |
|
| 2009 |
Goto Y, Shinjo K, Kondo Y, Shen L, Toyota M, Suzuki H, Gao W, An B, Fujii M, Murakami H, Osada H, Taniguchi T, Usami N, Kondo M, Hasegawa Y, ... ... Issa JP, et al. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Research. 69: 9073-82. PMID 19887624 DOI: 10.1158/0008-5472.CAN-09-1595 |
0.453 |
|
| 2009 |
Konishi K, Shen L, Jelinek J, Watanabe Y, Ahmed S, Kaneko K, Kogo M, Takano T, Imawari M, Hamilton SR, Issa JP. Concordant DNA methylation in synchronous colorectal carcinomas. Cancer Prevention Research (Philadelphia, Pa.). 2: 814-22. PMID 19737982 DOI: 10.1158/1940-6207.CAPR-09-0054 |
0.323 |
|
| 2009 |
Issa JPJ, Kantarjian HM. Targeting DNA methylation Clinical Cancer Research. 15: 3938-3946. PMID 19509174 DOI: 10.1158/1078-0432.CCR-08-2783 |
0.462 |
|
| 2009 |
Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, Oki Y, Guo Z, Gupta S, Wistuba II. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3881-8. PMID 19470736 DOI: 10.1158/1078-0432.Ccr-08-2196 |
0.331 |
|
| 2009 |
Tellez CS, Shen L, Estécio MR, Jelinek J, Gershenwald JE, Issa JP. CpG island methylation profiling in human melanoma cell lines. Melanoma Research. 19: 146-55. PMID 19441164 |
0.398 |
|
| 2009 |
Aparicio A, North B, Barske L, Wang X, Bollati V, Weisenberger D, Yoo C, Tannir N, Horne E, Groshen S, Jones P, Yang A, Issa JP. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics. 4: 176-84. PMID 19421002 DOI: 10.4161/Epi.4.3.8694 |
0.496 |
|
| 2009 |
Batty N, Malouf GG, Issa JPJ. Histone deacetylase inhibitors as anti-neoplastic agents Cancer Letters. 280: 192-200. PMID 19345475 DOI: 10.1016/j.canlet.2009.03.013 |
0.332 |
|
| 2009 |
Figueiredo JC, Grau MV, Wallace K, Levine AJ, Shen L, Hamdan R, Chen X, Bresalier RS, McKeown-Eyssen G, Haile RW, Baron JA, Issa JP. Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 18: 1041-9. PMID 19336559 DOI: 10.1158/1055-9965.Epi-08-0926 |
0.325 |
|
| 2009 |
Qin T, Jelinek J, Si J, Shu J, Issa JP. Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines. Blood. 113: 659-67. PMID 18931345 DOI: 10.1182/Blood-2008-02-140038 |
0.764 |
|
| 2009 |
Pathiraja T, Jelinek J, He R, Shetty P, Hartmaier R, Margossian A, Hilsenbeck S, Issa J, Oesterreich S. Progesterone Receptor (PR) Promoter Methylation – Role as a Predictive and Prognostic Marker in Breast Cancer. Cancer Research. 69: 2002-2002. DOI: 10.1158/0008-5472.Sabcs-09-2002 |
0.36 |
|
| 2008 |
Estécio MR, Yan PS, Huang TH, Issa JP. Methylated CpG Island Amplification and Microarray (MCAM) for High-Throughput Analysis of DNA Methylation. Csh Protocols. 2008: pdb.prot4974. PMID 21356790 DOI: 10.1101/Pdb.Prot4974 |
0.412 |
|
| 2008 |
Issa JP. Cancer prevention: Epigenetics steps up to the plate Cancer Prevention Research. 1: 219-222. PMID 19138962 DOI: 10.1158/1940-6207.Capr-08-0029 |
0.395 |
|
| 2008 |
Issa JP. Colon cancer: It's CINor CIMP Clinical Cancer Research. 14: 5939-5940. PMID 18829469 DOI: 10.1158/1078-0432.Ccr-08-1596 |
0.352 |
|
| 2008 |
Boumber YA, Kondo Y, Chen X, Shen L, Guo Y, Tellez C, Estécio MR, Ahmed S, Issa JP. An Sp1/Sp3 binding polymorphism confers methylation protection. Plos Genetics. 4: e1000162. PMID 18725933 DOI: 10.1371/Journal.Pgen.1000162 |
0.712 |
|
| 2008 |
Gao W, Kondo Y, Shen L, Shimizu Y, Sano T, Yamao K, Natsume A, Goto Y, Ito M, Murakami H, Osada H, Zhang J, Issa JP, Sekido Y. Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. Carcinogenesis. 29: 1901-10. PMID 18632756 DOI: 10.1093/carcin/bgn170 |
0.301 |
|
| 2008 |
Kroeger H, Jelinek J, Estécio MR, He R, Kondo K, Chung W, Zhang L, Shen L, Kantarjian HM, Bueso-Ramos CE, Issa JP. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood. 112: 1366-73. PMID 18523155 DOI: 10.1182/blood-2007-11-126227 |
0.471 |
|
| 2008 |
Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C, Yamochi T, Urano T, Furukawa K, Kwabi-Addo B, Gold DL, Sekido Y, Huang TH, Issa JP. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nature Genetics. 40: 741-50. PMID 18488029 DOI: 10.1038/Ng.159 |
0.753 |
|
| 2008 |
Lee ES, Issa JP, Roberts DB, Williams MD, Weber RS, Kies MS, El-Naggar AK. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2664-72. PMID 18451230 DOI: 10.1158/1078-0432.CCR-07-1232 |
0.364 |
|
| 2008 |
Chung W, Kwabi-Addo B, Ittmann M, Jelinek J, Shen L, Yu Y, Issa JP. Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. Plos One. 3: e2079. PMID 18446232 DOI: 10.1371/Journal.Pone.0002079 |
0.372 |
|
| 2008 |
Kondo Y, Shen L, Ahmed S, Boumber Y, Sekido Y, Haddad BR, Issa JPJ. Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. Plos One. 3. PMID 18446223 DOI: 10.1371/Journal.Pone.0002037 |
0.685 |
|
| 2008 |
Feng W, Marquez RT, Lu Z, Liu J, Lu KH, Issa JP, Fishman DM, Yu Y, Bast RC. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer. 112: 1489-502. PMID 18286529 DOI: 10.1002/Cncr.23323 |
0.333 |
|
| 2008 |
Zuo X, Shen L, Issa JP, Moy O, Morris JS, Lippman SM, Shureiqi I. 15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 22: 1981-92. PMID 18198215 DOI: 10.1096/fj.07-098301 |
0.492 |
|
| 2008 |
Shen L, Kondo Y, Ahmed S, Boumber Y, Konishi K, Guo Y, Chen X, Vilaythong JN, Issa JP. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Research. 67: 11335-43. PMID 18056460 DOI: 10.1158/0008-5472.Can-07-1502 |
0.74 |
|
| 2008 |
Issa J, Castoro R, Ravandi-Kashani F, Faderl S, Huang X, Estey E, Borthakur G, Morris G, Garcia-Manero G, Kantarjian HM. Randomized Phase II Study of Combined Epigenetic Therapy: Decitabine Vs. Decitabine and Valproic Acid in MDS and AML Blood. 112: 228-228. DOI: 10.1182/Blood.V112.11.228.228 |
0.41 |
|
| 2007 |
Oki Y, Issa JPJ. Treatment options in advanced myelodysplastic syndrome, with emphasis on epigenetic therapy International Journal of Hematology. 86: 306-314. PMID 18055336 DOI: 10.1532/IJH97.07034 |
0.339 |
|
| 2007 |
Wang J, Bhutani M, Pathak AK, Lang W, Ren H, Jelinek J, He R, Shen L, Issa J, Mao L. Delta DNMT3B variants regulate DNA methylation in a promoter-specific manner. Cancer Research. 67: 10647-10652. PMID 18006804 DOI: 10.1158/0008-5472.Can-07-1337 |
0.559 |
|
| 2007 |
Jelinek J, Li J, Mnjoyan Z, Issa JP, Prchal JT, Afshar-Kharghan V. Epigenetic control of PRV-1 expression on neutrophils. Experimental Hematology. 35: 1677-83. PMID 17976520 DOI: 10.1016/j.exphem.2007.09.008 |
0.3 |
|
| 2007 |
Shen L, Kondo Y, Guo Y, Zhang J, Zhang L, Ahmed S, Shu J, Chen X, Waterland RA, Issa JP. Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. Plos Genetics. 3: 2023-36. PMID 17967063 DOI: 10.1371/Journal.Pgen.0030181 |
0.828 |
|
| 2007 |
Shen L, Catalano PJ, Benson AB, O'Dwyer P, Hamilton SR, Issa JP. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6093-8. PMID 17947473 DOI: 10.1158/1078-0432.Ccr-07-1011 |
0.337 |
|
| 2007 |
Estécio MR, Yan PS, Ibrahim AE, Tellez CS, Shen L, Huang TH, Issa JP. High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Research. 17: 1529-36. PMID 17785535 DOI: 10.1101/Gr.6417007 |
0.438 |
|
| 2007 |
Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, Hunt KK, Bast RC, Shen Y, Issa JP, Yu Y. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Research : Bcr. 9: R57. PMID 17764565 DOI: 10.1186/Bcr1762 |
0.318 |
|
| 2007 |
Plimack ER, Kantarjian HM, Issa JP. Decitabine and its role in the treatment of hematopoietic malignancies Leukemia and Lymphoma. 48: 1472-1481. PMID 17701577 DOI: 10.1080/10428190701471981 |
0.407 |
|
| 2007 |
Choi SH, Byun HM, Kwan JM, Issa JP, Yang AS. Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition. British Journal of Haematology. 138: 616-23. PMID 17686055 DOI: 10.1111/J.1365-2141.2007.06707.X |
0.412 |
|
| 2007 |
Qin T, Youssef EM, Jelinek J, Chen R, Yang AS, Garcia-Manero G, Issa JP. Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4225-32. PMID 17634552 DOI: 10.1158/1078-0432.Ccr-06-2762 |
0.772 |
|
| 2007 |
Kwabi-Addo B, Chung W, Shen L, Ittmann M, Wheeler T, Jelinek J, Issa JP. Age-related DNA methylation changes in normal human prostate tissues. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 3796-802. PMID 17606710 DOI: 10.1158/1078-0432.Ccr-07-0085 |
0.338 |
|
| 2007 |
Kondo Y, Shen L, Suzuki S, Kurokawa T, Masuko K, Tanaka Y, Kato H, Mizuno Y, Yokoe M, Sugauchi F, Hirashima N, Orito E, Osada H, Ueda R, Guo Y, ... ... Issa JP, et al. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatology Research : the Official Journal of the Japan Society of Hepatology. 37: 974-83. PMID 17584191 DOI: 10.1111/j.1872-034X.2007.00141.x |
0.324 |
|
| 2007 |
Estécio MR, Gharibyan V, Shen L, Ibrahim AE, Doshi K, He R, Jelinek J, Yang AS, Yan PS, Huang TH, Tajara EH, Issa JP. LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. Plos One. 2: e399. PMID 17476321 DOI: 10.1371/Journal.Pone.0000399 |
0.407 |
|
| 2007 |
Konishi K, Issa JPJ. Targeting aberrant chromatin structure in colorectal carcinomas Cancer Journal. 13: 49-55. PMID 17464246 DOI: 10.1097/PPO.0b013e31803c72fe |
0.494 |
|
| 2007 |
Konishi K, Shen L, Wang S, Meltzer SJ, Harpaz N, Issa JP. Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias. Gastroenterology. 132: 1254-60. PMID 17408633 DOI: 10.1053/J.Gastro.2007.01.035 |
0.31 |
|
| 2007 |
Issa JPJ. DNA methylation as a therapeutic target in cancer Clinical Cancer Research. 13: 1634-1637. PMID 17363514 DOI: 10.1158/1078-0432.CCR-06-2076 |
0.485 |
|
| 2007 |
Jelinek J, Issa JP, He R, Cmejla R, Cmejlova J, Pospisilova D. RPS19 and JAK2 genes are not silenced by DNA methylation in diamond blackfan anemia. Journal of Pediatric Hematology/Oncology. 29: 207-8. PMID 17356406 DOI: 10.1097/MPH.0b013e318033a75a |
0.432 |
|
| 2007 |
Boumber YA, Kondo Y, Chen X, Shen L, Gharibyan V, Konishi K, Estey E, Kantarjian H, Garcia-Manero G, Issa JP. RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. Cancer Research. 67: 1997-2005. PMID 17332327 DOI: 10.1158/0008-5472.Can-06-3093 |
0.738 |
|
| 2007 |
Shen L, Issa JP. Epigenetics in colorectal cancer. Current Opinion in Gastroenterology. 18: 68-73. PMID 17031233 DOI: 10.1097/00001574-200201000-00012 |
0.436 |
|
| 2007 |
Oki Y, Aoki E, Issa JPJ. Decitabine-Bedside to bench Critical Reviews in Oncology/Hematology. 61: 140-152. PMID 17023173 DOI: 10.1016/j.critrevonc.2006.07.010 |
0.336 |
|
| 2007 |
Borthakur G, Kantarjian H, O’Brien S, Ravandi F, Koller C, Estrov Z, Torma R, Issa J. Report of a Phase1/2 Study of 5-Azacitidine and Cytarabine in Patients with Relapsed, Refractory Acute Myelogenous Leukemia. Blood. 110: 911-911. DOI: 10.1182/Blood.V110.11.911.911 |
0.383 |
|
| 2007 |
Ravandi F, Faderl S, Thomas D, Burger J, Koller C, Garcia-Manero G, Morris G, Torma R, Kantarjian H, Issa J. Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) and Decitabine in Patients with Relapsed, Refractory or Poor Prognosis Leukemia. Blood. 110: 897-897. DOI: 10.1182/Blood.V110.11.897.897 |
0.389 |
|
| 2007 |
Kroeger H, Jelinek J, Kornblau SM, Bueso-Ramos CE, Issa J. Increased DNA Methylation Is Associated with Good Prognosis in AML. Blood. 110: 595-595. DOI: 10.1182/Blood.V110.11.595.595 |
0.482 |
|
| 2007 |
Ahdab SE, Castoro R, Abbas HA, Ahmed S, Jelinek J, Issa J. Methylation Profiling of Apoptotic Genes in Leukemia Cell Lines and Patients. Blood. 110: 4147-4147. DOI: 10.1182/Blood.V110.11.4147.4147 |
0.528 |
|
| 2007 |
Ravandi F, Issa J, Faderl S, Garcia-Manero G, Hood M, Jorgensen J, Lee M, O’Brien S, Estey E, Borthakur G, Ferrajoli A, Verstovsek S, Cortes J, Kantarjian H. Randomized Study of Decitabine Versus Observation or Continued Cytotoxic Chemotherapy in Patients with Intermediate and Poor Risk Acute Myeloid Leukemia in First or Subsequent Complete Remission. Blood. 110: 2859-2859. DOI: 10.1182/Blood.V110.11.2859.2859 |
0.346 |
|
| 2007 |
Kuang S, Tong W, Yang H, Lee MK, Fang Z, Jelinek J, Issa J, Garcia-Manero G. Genome-Wide Identification of Aberrant Promoter Associated CpG Island Methylation in Acute Lymphoblastic Leukemia. Blood. 110: 2127-2127. DOI: 10.1182/Blood.V110.11.2127.2127 |
0.574 |
|
| 2007 |
Heinrichs S, Kulkarni RV, Bueso-Ramos CE, Loh M, Levine R, Li C, Neuberg DS, Kornblau SM, Issa J, Gilliland DG, Estey EH, Look AT. Large Regions of Uniparental Disomy (UPD) Establish Clonal Hematopoietic Stem Cell Selection in a Subset of Myelodysplastic Syndrome (MDS) Patients with Normal Bone Marrow Cell Karyotypes. Blood. 110: 120-120. DOI: 10.1182/Blood.V110.11.120.120 |
0.321 |
|
| 2006 |
Soriano AO, Yang H, Verstovsek S, Wierda W, Koller C, Estrov Z, Ouzounian S, Kantarjian H, Issa J, Garcia-Manero G. Phase I/II study of the combination of 5-azacytidine(5-AC), all-trans retinoic acid (ATRA) and valproic Acid (VPA) in patients with myelodysplastic syndrome (MDS) and leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 6563. PMID 27953109 DOI: 10.1200/Jco.2006.24.18_Suppl.6563 |
0.336 |
|
| 2006 |
Oki Y, Issa JPJ. Review: recent clinical trials in epigenetic therapy Reviews On Recent Clinical Trials. 1: 169-182. PMID 18473969 DOI: 10.2174/157488706776876490 |
0.35 |
|
| 2006 |
Montero AJ, Díaz-Montero CM, Mao L, Youssef EM, Estecio M, Shen L, Issa JP. Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer. Cancer Biology & Therapy. 5: 1494-501. PMID 17369752 DOI: 10.4161/cbt.5.11.3299 |
0.312 |
|
| 2006 |
Tabe Y, Konopleva M, Kondo Y, Contractor R, Jin L, Ruvolo V, Tsutsumi-Ishii Y, Miyake K, Miyake N, Ohsaka A, Nagaoka I, Issa JP, Andreeff M. PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter. Annals of Hematology. 85: 689-704. PMID 16832676 DOI: 10.1007/S00277-006-0148-7 |
0.458 |
|
| 2006 |
Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V, Luna R, Rashid A, Shen L, Estecio MR, Kantarjian HM, Garcia-Manero G, Issa JP. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Research. 66: 5495-503. PMID 16707479 DOI: 10.1158/0008-5472.CAN-05-2385 |
0.379 |
|
| 2006 |
Shu J, Jelinek J, Chang H, Shen L, Qin T, Chung W, Oki Y, Issa JP. Silencing of bidirectional promoters by DNA methylation in tumorigenesis. Cancer Research. 66: 5077-84. PMID 16707430 DOI: 10.1158/0008-5472.Can-05-2629 |
0.813 |
|
| 2006 |
Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R, Shen L, Nimer SD, Leavitt R, Raza A, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 106: 1794-803. PMID 16532500 DOI: 10.1002/cncr.21792 |
0.311 |
|
| 2006 |
Byun H, Eshaghian S, Jiang JY, Choi SH, Ramezani L, Douer D, Garcia-Manero G, Issa J, Yang D, Trent J, Yang AS. Methylation Profiling of Three Homogenous Cancers: Chronic Myelogenous Leukemia (CML), Acute Promyelocytic Leukemia (APL) and Gastrointestinal Stromal Tumors (GIST). Blood. 108: 736-736. DOI: 10.1182/Blood.V108.11.736.736 |
0.573 |
|
| 2006 |
Plasilova M, Ommen HB, Jelinek J, Issa J, Riedel ER, Mathew S, Chadburn A, Zhou P, Hokland P, Moore MAS. Loss of Heterozygosity (LOH) of the NUP98 Gene Is an Adverse Prognostic Factor in Acute Myeloid Leukemia (AML). Blood. 108: 2356-2356. DOI: 10.1182/Blood.V108.11.2356.2356 |
0.343 |
|
| 2006 |
Loboda A, Fantin VR, Bueso-Ramos CE, Randolph S, Hardwick JS, Ricker JL, Richon VM, Issa J, Kantarjian HM, Frankel SR, Garcia-Manero G. Clinical Responses to Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Are Associated with Specific Gene Expression Signatures in Patients with Advanced Leukemias: Results of a Phase I Trial. Blood. 108: 2320-2320. DOI: 10.1182/Blood.V108.11.2320.2320 |
0.374 |
|
| 2006 |
Garcia-Manero G, Yang AS, Giles F, Faderl S, Ravandi F, Cortes J, Newsome WM, Issa J, Patterson T, Dubay M, Li Z, Kantarjian H, Martell RE. Phase I/II Study of the Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor MGCD0103 in Combination with Azacitidine in Patients (pts) with High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML). Blood. 108: 1954-1954. DOI: 10.1182/Blood.V108.11.1954.1954 |
0.373 |
|
| 2006 |
Soriano AO, Yang H, Tong W, Faderl S, Wierda W, Andreeff M, Estrov Z, Ouzounian S, Clavell J, Kantarjian H, Issa J, Garcia-Manero G. Significant Clinical Activity of the Combination of 5-Azacytidine, Valproic Acid and All-Trans Retinoic (ATRA) Acid in Leukemia: Results of a Phase I/II Study. Blood. 108: 160-160. DOI: 10.1182/Blood.V108.11.160.160 |
0.325 |
|
| 2005 |
Garcia-Manero G, Issa JP. Histone deacetylase inhibitors: A review of their clinical status as antineoplastic agents Cancer Investigation. 23: 635-642. PMID 16305991 DOI: 10.1080/07357900500283119 |
0.374 |
|
| 2005 |
Issa JP. DNA methylation in the treatment of hematologic malignancies Clinical Advances in Hematology and Oncology. 3: 684-686. PMID 16224441 |
0.385 |
|
| 2005 |
Toyota M, Issa JPJ. Epigenetic changes in solid and hematopoietic tumors Seminars in Oncology. 32: 521-531. PMID 16210093 DOI: 10.1053/j.seminoncol.2005.07.003 |
0.452 |
|
| 2005 |
Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, Vilaythong J, Houlihan PS, Krouse RS, Prasad AR, Einspahr JG, Buckmeier J, Alberts DS, Hamilton SR, Issa JP. MGMT promoter methylation and field defect in sporadic colorectal cancer. Journal of the National Cancer Institute. 97: 1330-8. PMID 16174854 DOI: 10.1093/Jnci/Dji275 |
0.395 |
|
| 2005 |
Canalli AA, Yang H, Jeha S, Hoshino K, Sanchez-Gonzalez B, Brandt M, Pierce S, Kantarjian H, Issa JP, Garcia-Manero G. Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia. Leukemia Research. 29: 881-5. PMID 15978938 DOI: 10.1016/j.leukres.2004.11.023 |
0.337 |
|
| 2005 |
Issa JP, Kantarjian H, Kirkpatrick P. Azacitidine Nature Reviews Drug Discovery. 4. PMID 15962522 DOI: 10.1038/nrd1726 |
0.382 |
|
| 2005 |
Chirieac LR, Shen L, Catalano PJ, Issa JP, Hamilton SR. Phenotype of microsatellite-stable colorectal carcinomas with CpG island methylation. The American Journal of Surgical Pathology. 29: 429-36. PMID 15767794 DOI: 10.1097/01.Pas.0000155144.53047.7D |
0.361 |
|
| 2005 |
Garcia-Manero G, Kantarjian H, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Ravandi F, Faderl S, Estrov Z, Cortes J, O’Brien S, Fiorentino J, Issa J. Final Results of a Phase I/II Study of the Combination of the Hypomethylating Agent 5-aza-2′-Deoxycytidine (DAC) and the Histone Deacetylase Inhibitor Valproic Acid (VPA) in Patients with Leukemia. Blood. 106: 408-408. DOI: 10.1182/Blood.V106.11.408.408 |
0.392 |
|
| 2005 |
Oki Y, Jelinek J, Shen L, Issa J. Comprehensive Promoter Methylation Analysis of Genes on 5q31.1 in MDS and AML. Blood. 106: 3443-3443. DOI: 10.1182/Blood.V106.11.3443.3443 |
0.466 |
|
| 2005 |
Oki Y, Kantarjian HM, O’Brien S, Verstovsek S, Gharibyan V, Cortes J, Morris GM, Garcia-Manero G, Issa J. Phase II Study of Decitabine in Combination with Imatinib Mesylate in Patients with Accelerated (AP) or Blastic Phase (BP) of Chronic Myeloid Leukemia (CML). Blood. 106: 1099-1099. DOI: 10.1182/Blood.V106.11.1099.1099 |
0.328 |
|
| 2004 |
Issa JP. CpG island methylator phenotype in cancer Nature Reviews Cancer. 4: 988-993. PMID 15573120 DOI: 10.1038/Nrc1507 |
0.51 |
|
| 2004 |
Rashid A, Issa JPJ. CpG island methylation in gastroenterologic neoplasia: A maturing field Gastroenterology. 127: 1578-1588. PMID 15521024 DOI: 10.1053/j.gastro.2004.09.007 |
0.382 |
|
| 2004 |
Kondo Y, Shen L, Yan PS, Huang TH, Issa JP. Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation. Proceedings of the National Academy of Sciences of the United States of America. 101: 7398-403. PMID 15123805 DOI: 10.1073/Pnas.0306641101 |
0.449 |
|
| 2004 |
Youssef EM, Chen XQ, Higuchi E, Kondo Y, Garcia-Manero G, Lotan R, Issa JP. Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers. Cancer Research. 64: 2411-7. PMID 15059893 DOI: 10.1158/0008-5472.Can-03-0164 |
0.446 |
|
| 2004 |
Kondo Y, Issa JPJ. Epigenetic changes in colorectal cancer Cancer and Metastasis Reviews. 23: 29-39. PMID 15000147 DOI: 10.1023/A:1025806911782 |
0.464 |
|
| 2004 |
Yang AS, Estécio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Research. 32: e38. PMID 14973332 DOI: 10.1093/nar/gnh032 |
0.419 |
|
| 2004 |
Youssef EM, Estecio MRH, Issa JPJ. Methylation and regulation of expression of different retinoic acid receptor β isoforms in human colon cancer Cancer Biology and Therapy. 3: 82-86. PMID 14726683 |
0.369 |
|
| 2004 |
Obata T, Toyota M, Satoh A, Sasaki Y, Ogi K, Akino K, Suzuki H, Murai M, Kikuchi T, Mita H, Itoh F, Issa JP, Tokino T, Imai K. Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 6410-8. PMID 14695142 |
0.383 |
|
| 2004 |
Issa JP. Decitabine. Current Opinion in Oncology. 15: 446-51. PMID 14624227 DOI: 10.1097/00001622-200311000-00007 |
0.445 |
|
| 2004 |
Saba H, Rosenfeld C, Issa J, DiPersio J, Raza A, Klimek V, Slack J, Castro Cd, Mettinger K, Kantarjian H. First Report of the Phase III North American Trial of Decitabine in Advanced Myelodysplastic Syndrome (MDS). Blood. 104: 67-67. DOI: 10.1182/Blood.V104.11.67.67 |
0.342 |
|
| 2004 |
Liu TX, Becker M, Hsu K, Jelinek J, Deng M, Bloomfield C, Issa J, Clarke MF, Look AT. Epigenetic Suppression of the CTNNA1 Gene, Encoding the α-Catenin Protein, which Is Located in the 5q31 Critical Deleted Region in Malignant Myeloid Disorders with del(5q). Blood. 104: 203-203. DOI: 10.1182/Blood.V104.11.203.203 |
0.326 |
|
| 2004 |
Jelinek J, Mannari R, Issa J. Identification of 41 Novel Promoter-Associated CpG Islands Methylated in Leukemias. Blood. 104: 1126-1126. DOI: 10.1182/Blood.V104.11.1126.1126 |
0.561 |
|
| 2003 |
Belinsky SA, Klinge DM, Stidley CA, Issa JP, Herman JG, March TH, Baylin SB. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Research. 63: 7089-93. PMID 14612500 |
0.379 |
|
| 2003 |
Issa JP. Age-related epigenetic changes and the immune system Clinical Immunology. 109: 103-108. PMID 14585281 DOI: 10.1016/S1521-6616(03)00203-1 |
0.467 |
|
| 2003 |
Frazier ML, Xi L, Zong J, Viscofsky N, Rashid A, Wu EF, Lynch PM, Amos CI, Issa JP. Association of the CpG island methylator phenotype with family history of cancer in patients with colorectal cancer. Cancer Research. 63: 4805-8. PMID 12941799 |
0.363 |
|
| 2003 |
Issa JPJ. Methylation and prognosis: Of molecular clocks and hypermethylator phenotypes Clinical Cancer Research. 9: 2879-2881. PMID 12912930 |
0.311 |
|
| 2003 |
Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, Keating M, Talpaz M. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer. 98: 522-8. PMID 12879469 DOI: 10.1002/Cncr.11543 |
0.358 |
|
| 2003 |
Fujii S, Luo RZ, Yuan J, Kadota M, Oshimura M, Dent SR, Kondo Y, Issa JP, Bast RC, Yu Y. Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. Human Molecular Genetics. 12: 1791-800. PMID 12874100 DOI: 10.1093/Hmg/Ddg204 |
0.424 |
|
| 2003 |
Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, Issa JP, Bast RC, Yu Y. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Research. 63: 4174-80. PMID 12874023 |
0.433 |
|
| 2003 |
Li H, Myeroff L, Smiraglia D, Romero MF, Pretlow TP, Kasturi L, Lutterbaugh J, Rerko RM, Casey G, Issa JP, Willis J, Willson JK, Plass C, Markowitz SD. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proceedings of the National Academy of Sciences of the United States of America. 100: 8412-7. PMID 12829793 DOI: 10.1073/Pnas.1430846100 |
0.45 |
|
| 2003 |
Toyota M, Sasaki Y, Satoh A, Ogi K, Kikuchi T, Suzuki H, Mita H, Tanaka N, Itoh F, Issa JP, Jair KW, Schuebel KE, Imai K, Tokino T. Epigenetic inactivation of CHFR in human tumors. Proceedings of the National Academy of Sciences of the United States of America. 100: 7818-23. PMID 12810945 DOI: 10.1073/pnas.1337066100 |
0.448 |
|
| 2003 |
Kondo Y, Issa JPJ. Enrichment for histone H3 lysine 9 methylation at Alu repeats in human cells Journal of Biological Chemistry. 278: 27658-27662. PMID 12724318 DOI: 10.1074/jbc.M304072200 |
0.343 |
|
| 2003 |
Yu Y, Fujii S, Yuan J, Luo RZ, Wang L, Bao J, Kadota M, Oshimura M, Dent SR, Issa JP, Bast RC. Epigenetic regulation of ARHI in breast and ovarian cancer cells. Annals of the New York Academy of Sciences. 983: 268-77. PMID 12724231 DOI: 10.1111/J.1749-6632.2003.Tb05981.X |
0.47 |
|
| 2003 |
Shen L, Kondo Y, Hamilton SR, Rashid A, Issa JP. P14 methylation in human colon cancer is associated with microsatellite instability and wild-type p53. Gastroenterology. 124: 626-33. PMID 12612901 DOI: 10.1053/gast.2003.50102 |
0.333 |
|
| 2003 |
Shen L, Toyota M, Kondo Y, Obata T, Daniel S, Pierce S, Imai K, Kantarjian HM, Issa JP, Garcia-Manero G. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood. 101: 4131-6. PMID 12586619 DOI: 10.1182/blood-2002-08-2466 |
0.45 |
|
| 2003 |
Chan AO, Kim SG, Bedeir A, Issa JP, Hamilton SR, Rashid A. CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene. 22: 924-34. PMID 12584572 DOI: 10.1038/sj.onc.1206123 |
0.303 |
|
| 2003 |
Garcia-Manero G, Jeha S, Daniel J, Williamson J, Albitar M, Kantarjian HM, Issa JP. Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia. Cancer. 97: 695-702. PMID 12548613 DOI: 10.1002/cncr.11090 |
0.397 |
|
| 2003 |
Kondo Y, Shen L, Issa JPJ. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer Molecular and Cellular Biology. 23: 206-215. PMID 12482974 DOI: 10.1128/MCB.23.1.206-215.2003 |
0.495 |
|
| 2002 |
Shen L, Kondo Y, Issa J, Garcia-Manero G. Lack of p21CIP1 DNA methylation in acute lymphocytic leukemia Blood. 100: 3432-3433. PMID 12412576 DOI: 10.1182/Blood-2002-07-1990 |
0.439 |
|
| 2002 |
Issa JP. Epigenetic variation and human disease Journal of Nutrition. 132. PMID 12163698 DOI: 10.1093/Jn/132.8.2388S |
0.445 |
|
| 2002 |
Garcia-Manero G, Daniel J, Smith TL, Kornblau SM, Lee MS, Kantarjian HM, Issa JP. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 2217-24. PMID 12114423 |
0.413 |
|
| 2002 |
Garcia-Manero G, Bueso-Ramos C, Daniel J, Williamson J, Kantarjian HM, Issa JP. DNA methylation patterns at relapse in adult acute lymphocytic leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 1897-903. PMID 12060634 |
0.427 |
|
| 2002 |
Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, Liu DD, Kurie JM, Mao L, Khuri FR. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 1178-84. PMID 12006535 |
0.32 |
|
| 2002 |
Chan AO, Broaddus RR, Houlihan PS, Issa JP, Hamilton SR, Rashid A. CpG island methylation in aberrant crypt foci of the colorectum. The American Journal of Pathology. 160: 1823-30. PMID 12000733 DOI: 10.1016/S0002-9440(10)61128-5 |
0.391 |
|
| 2002 |
Kikuchi T, Toyota M, Itoh F, Suzuki H, Obata T, Yamamoto H, Kakiuchi H, Kusano M, Issa JP, Tokino T, Imai K. Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors. Oncogene. 21: 2741-9. PMID 11965547 DOI: 10.1038/sj.onc.1205376 |
0.455 |
|
| 2002 |
Toyota M, Issa JPJ. Methylated CpG island amplification for methylation analysis and cloning differentially methylated sequences Methods in Molecular Biology (Clifton, N.J.). 200: 101-110. PMID 11951646 |
0.346 |
|
| 2002 |
Moinova HR, Chen WD, Shen L, Smiraglia D, Olechnowicz J, Ravi L, Kasturi L, Myeroff L, Plass C, Parsons R, Minna J, Willson JK, Green SB, Issa JP, Markowitz SD. HLTF gene silencing in human colon cancer. Proceedings of the National Academy of Sciences of the United States of America. 99: 4562-7. PMID 11904375 DOI: 10.1073/Pnas.062459899 |
0.422 |
|
| 2002 |
Chan AO, Issa JP, Morris JS, Hamilton SR, Rashid A. Concordant CpG island methylation in hyperplastic polyposis. The American Journal of Pathology. 160: 529-36. PMID 11839573 DOI: 10.1016/S0002-9440(10)64872-9 |
0.35 |
|
| 2001 |
Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: Pathophysiology and therapeutic implications Annals of Internal Medicine. 134: 573-586. PMID 11281740 DOI: 10.7326/0003-4819-134-7-200104030-00011 |
0.544 |
|
| 2000 |
Issa JP. The epigenetics of colorectal cancer Annals of the New York Academy of Sciences. 910: 140-155. PMID 10911911 DOI: 10.1111/J.1749-6632.2000.Tb06706.X |
0.521 |
|
| 1999 |
Issa JP. Aging, DNA methylation and cancer Critical Reviews in Oncology/Hematology. 32: 31-43. PMID 10586353 DOI: 10.1016/S1040-8428(99)00019-0 |
0.549 |
|
| 1998 |
Lengauer C, Issa JP. The role of epigenetics in cancer Molecular Medicine Today. 4: 102-103. PMID 9575489 DOI: 10.1016/S1357-4310(98)01220-9 |
0.504 |
|
| 1995 |
Wales MM, Biel MA, el Deiry W, Nelkin BD, Issa JP, Cavenee WK, Kuerbitz SJ, Baylin SB. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nature Medicine. 1: 570-7. PMID 7585125 DOI: 10.1038/Nm0695-570 |
0.414 |
|
| Show low-probability matches. |